1. Kaplan NM. The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch Intern Med 1989;149:1514–1520.
2. Reaven GM, Hoffman BB. A role for insulin in the aetiology and course of hypertension? Lancet 1987;2:435–437.
3. Matsuzawa Y, Funahashi T, Nakamura T. Molecular mechanism of metabolic syndrome X: contribution of adipocytokines adipocyte-derived bioactive substances. Ann NY Acad Sci 1999;892:146–154.
4. Trayhurn P, Beattie JH. Physiological role of adipose tissue: white adipose tissue as an endocrine and secretory organ. Proc Nutr Soc 2001;60:329–339.
5. Ahima RS, Flier JS. Adipose tissue as an endocrine organ. Trends Endocrinol Metab 2000;11:327–332.
6. Garg A. Lipodystrophies. Am J Med 2000;108:143–152.
7. Shimomura I, Hammer RE, Richardson JA, et al. Insulin resistance and diabetes mellitus in transgenic mice expressing nuclear SREBP-1c in adipose tissue: model for congenital generalized lipodystrophy. Genes Dev 1998;12:3182–3194.
8. Moitra J, Mason MM, Olive M, et al. Life without white fat: a transgenic mouse. Genes Dev 1998;12:3168–3181.
9. Lefebvre AM, Laville M, Vega N, et al. Depot-specific differences in adipose tissue gene expression in lean and obese subjects. Diabetes 1998;47:98–103.
10. Bjorntorp P. Adipose tissue distribution and function. Int J Obes 1991;15(suppl 2):67–81.
11. Arner P. Regional differences in protein production by human adipose tissue. Biochem Soc Trans 2001;29:72–75.
12. Dusserre E, Moulin P, Vidal H. Differences in mRNA expression of the proteins secreted by the adipocytes in human subcutaneous and visceral adipose tissues. Biochim Biophys Acta 2000;1500:88–96.
13. Hervey GR. The effects of lesions in the hypothalamus in parabiotic rats. J Physiol Lond 1959;145:336.
14. Bray GA, York DA. Hypothalamic and genetic obesity in experimental animals: an autonomic and endocrine hypothesis. Physiol Rev 1979;59:719–809.
15. Zhang Y, Proenca R, Maffei M, et al. Positional cloning of the mouse obese gene and its human homologue. Nature 1994;372:425–432.
16. Ingalls AM, Dickie MM, Snell GD. Obesity, new mutation in the mouse. J Hered 1950;41:317–318.
17. Coleman DL. Obese and diabetes: two mutant genes causing diabetes-obesity syndromes in mice. Diabetologia 1978;14:141–148.
18. Coleman DL. Effects of parabiosis of obese with diabetes and normal mice. Diabetologia 1973;9:294–298.
19. Halaas JL, Gajiwala KS, Maffei M, et al. Weight-reducing effects of the plasma protein encoded by the obese gene. Science 1995;269: 543–546.
20. Ahima RS, Flier JS. Leptin. Annu Rev Physiol 2000;62:413–437.
21. Frederich RC, Hamann A, Anderson S, et al. Leptin levels reflect body lipid content in mice: evidence for diet-induced resistance to leptin action. Nat Med 1995;1:1311–1314.
22. Maffei M, Halaas J, Ravussin E, et al. Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. Nat Med 1995;1:1155–1161.
23. Couillard C, Mauriege P, Imbeault P, et al. Hyperleptinemia is more closely associated with adipose cell hypertrophy than with adipose tissue hyperplasia. Int J Obes Rel Metab Disord 2000;24:782–788.
24. Lonnqvist F, Arner P, Nordfors L, et al. Overexpression of the obese (ob) gene in adipose tissue of human obese subjects. Nat Med 1995; 1:950–953.
25. Hamilton BS, Paglia D, Kwan AY, et al. Increased obese mRNA expression in omental fat cells from massively obese humans. Nat Med 1995;1:953–956.
26. Barr VA, Malide D, Zarnowski MJ, et al. Insulin stimulates both leptin secretion and production by rat white adipose tissue. Endocrinology 1997;138:4463–4472.
27. Bamshad M, Aoki VT, Adkison MG, et al. Central nervous system origins of the sympathetic nervous system outflow to white adipose tissue. Am J Physiol 1998;275:R291–R299.
28. Bartness TJ, Bamshad M. Innervation of mammalian white adipose tissue: implications for the regulation of total body fat. Am J Physiol 1998;275:R1399–R1411.
29. Chen H, Charlat O, Tartaglia LA, et al. Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in db/db mice. Cell 1996;84:491–495.
30. Lee GH, Proenca R, Montez JM, et al. Abnormal splicing of the leptin receptor in diabetic mice. Nature 1996;379:632–635.
31. Tartaglia LA. The leptin receptor. J Biol Chem 1997;272:6093–6096.
32. Kline AD, Becker GW, Churgay LM, et al. Leptin is a four-helix bundle: secondary structure by NMR. FEBS Lett 1997;407:239–242.
33. Zhang F, Basinski MB, Beals JM, et al. Crystal structure of the obese protein leptin-E100. Nature 1997;387:206–209.
34. Tartaglia LA, Dembski M, Weng X, et al. Identification and expression cloning of a leptin receptor, OB-R. Cell 1995;83:1263–1271.
35. Baumann H, Morella KK, White DW, et al. The full-length leptin receptor has signaling capabilities of interleukin 6-type cytokine receptors. Proc Natl Acad Sci USA 1996;93:8374–8378.
36. Bjorbaek C, Uotani S, da Silva B, et al. Divergent signaling capacities of the long and short isoforms of the leptin receptor. J Biol Chem 1997;272:32686–32695.
37. Ghilardi N, Skoda RC. The leptin receptor activates janus kinase 2 and signals for proliferation in a factor-dependent cell line. Mol Endocrinol 1997;11:393–399.
38. Stahl N, Farruggella TJ, Boulton TG, et al. Choice of STATs and other substrates specified by modular tyrosine-based motifs in cytokine receptors. Science 1995;267:1349–1353.
39. White DW, Kuropatwinski KK, Devos R, et al. Leptin receptor (OB-R) signaling. Cytoplasmic domain mutational analysis and evidence for receptor homo-oligomerization. J Biol Chem 1997;272: 4065–4071.
40. Banks AS, Davis SM, Bates SH, et al. Activation of downstream signals by the long form of the leptin receptor. J Biol Chem 2000;275: 14563–14572.
41. Ghilardi N, Ziegler S, Wiestner A, et al. Defective STAT signaling by the leptin receptor in diabetic mice. Proc Natl Acad Sci USA 1996; 93:6231–6235.
42. Vaisse C, Halaas JL, Horvath CM, et al. Leptin activation of Stat3 in the hypothalamus of wild-type and ob/ob mice but not db/db mice. Nat Genet 1996;14:95–97.
43. Zhao AZ, Huan JN, Gupta S, et al. A phosphatidylinositol 3-kinase phosphodiesterase 3B-cyclic AMP pathway in hypothalamic action of leptin on feeding. Nat Neurosci 2002;5:727–728.
44. Niswender KD, Morton GJ, Stearns WH, et al. Intracellular signalling: key enzyme in leptin-induced anorexia. Nature 2001;413: 794–795.
45. Kim YB, Uotani S, Pierroz DD, et al. In vivo administration of leptin activates signal transduction directly in insulin-sensitive tissues: overlapping but distinct pathways from insulin. Endocrinology 2000; 141:2328–2339.
46. Wang Y, Kuropatwinski KK, White DW, et al. Leptin receptor action in hepatic cells. J Biol Chem 1997;272:16216–16223.
47. Brann DW, Wade MF, Dhandapani KM, et al. Leptin and reproduction. Steroids 2002;67:95–104.
48. Bjorbaek C, Buchholz RM, Davis SM, et al. Divergent roles of SHP-2 in ERK activation by leptin receptors. J Biol Chem 2001;276: 4747–4755.
49. Ahima RS, Saper CB, Flier JS, et al. Leptin regulation of neuroendocrine systems. Front Neuroendocrinol 2000;21:263–307.
50. Halaas JL, Boozer C, Blair-West J, et al. Physiological response to long-term peripheral and central leptin infusion in lean and obese mice. Proc Natl Acad Sci USA 1997;94:8878–8883.
51. Elmquist JK, Maratos-Flier E, Saper CB, et al. Unraveling the central nervous system pathways underlying responses to leptin. Nat Neurosci 1998;1:445–450.
52. Sawchenko PE. Toward a new neurobiology of energy balance, appetite, and obesity: the anatomists weigh in. J Comp Neurol 1998; 402:435–441.
53. McMinn JE, Baskin DG, Schwartz MW. Neuroendocrine mechanisms regulating food intake and body weight. Obes Rev 2000;1: 37–46.
54. Jequier E. Leptin signaling, adiposity, and energy balance. Ann NY Acad Sci 2002;967:379–388.
55. Chehab FF. Leptin as a regulator of adipose mass and reproduction. Trends Pharmacol Sci 2000;21:309–314.
56. Chehab FF, Lim ME, Lu R. Correction of the sterility defect in homozygous obese female mice by treatment with the human recombinant leptin. Nat Genet 1996;12:318–320.
57. Hileman SM, Pierroz DD, Masuzaki H, et al. Characterizaton of short isoforms of the leptin receptor in rat cerebral microvessels and of brain uptake of leptin in mouse models of obesity. Endocrinology 2002;143:775–783.
58. Schwartz MW, Peskind E, Raskind M, et al. Cerebrospinal fluid leptin levels: relationship to plasma levels and to adiposity in humans. Nat Med 1996;2:589–593.
59. Bjorbaek C, El-Haschimi K, Frantz JD, et al. The role of SOCS-3 in leptin signaling and leptin resistance. J Biol Chem 1999;274:30059–30065.
60. Bjorbaek C, Lavery HJ, Bates SH, et al. SOCS3 mediates feedback inhibition of the leptin receptor via Tyr985. J Biol Chem 2000;275: 40649–40657.
61. Zabolotny JM, Bence-Hanulec KK, Stricker-Krongrad A, et al. PTP1B regulates leptin signal transduction in vivo. Dev Cell 2002;2: 489–495.
62. Cheng A, Uetani N, Simoncic PD, et al. Attenuation of leptin action and regulation of obesity by protein tyrosine phosphatase 1B. Dev Cell 2002;2:497–503.
63. Lee DW, Leinung MC, Rozhavskaya-Arena M, et al. Leptin and the treatment of obesity: its current status. Eur J Pharmacol 2002;440: 129–139.
64. Frederich RC, Lollmann B, Hamann A, et al. Expression of ob mRNA and its encoded protein in rodents: impact of nutrition and obesity. J Clin Invest 1995;96:1658–1663.
65. Boden G, Chen X, Mozzoli M, et al. Effect of fasting on serum leptin in normal human subjects. J Clin Endocrinol Metab 1996;81: 3419–3423.
66. Scherer PE, Williams S, Fogliano M, et al. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 1995;270:26746–26749.
67. Hu E, Liang P, Spiegelman BM. AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem 1996;271:10697–10703.
68. Nakano Y, Tobe T, Choi-Miura NH, et al. Isolation and characterization of GBP28, a novel gelatin-binding protein purified from human plasma. J Biochem (Tokyo) 1996;120:803–812.
69. Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999;257:79–83.
70. Maeda K, Okubo K, Shimomura I, et al. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun 1996;221:286–289.
71. Tsao TS, Lodish HF, Fruebis J. ACRP30, a new hormone controlling fat and glucose metabolism. Eur J Pharmacol 2002;440:213–221.
72. Kishore U, Reid KB. Modular organization of proteins containing C1q-like globular domain. Immunopharmacology 1999;42:15–21.
73. Kishore U, Reid KB. C1q: structure, function, and receptors. Immunopharmacology 2000;49:159–170.
74. Shapiro L, Scherer PE. The crystal structure of a complement-1q family protein suggests an evolutionary link to tumor necrosis factor. Curr Biol 1998;8:335–338.
75. Yoda M, Nakano Y, Tobe T, et al. Characterization of mouse GBP28 and its induction by exposure to cold. Int J Obes Rel Metab Disord 2001;25:75–83.
76. Tsao TS, Murrey HE, Hug C, et al. Oligomerization state-dependent activation of NF-kappa B signaling pathway by adipocyte complement-related protein of 30 kDa (Acrp30). J Biol Chem 2002; 277:29359–29362.
77. Kappes A, Loffler G. Influences of ionomycin, dibutyryl-cycloAMP and tumour necrosis factor-alpha on intracellular amount and secretion of apM1 in differentiating primary human preadipocytes. Horm Metab Res 2000;32:548–554.
78. Maeda N, Takahashi M, Funahashi T, et al. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 2001;50:2094–2099.
79. Ruan H, Hacohen N, Golub TR, et al. Tumor necrosis factor-alpha suppresses adipocyte-specific genes and activates expression of preadipocyte genes in 3T3-L1 adipocytes: nuclear factor-kappaB activation by TNF-alpha is obligatory. Diabetes 2002;51:1319–1336.
80. Yamauchi T, Kamon J, Waki H, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001;7:941–946.
81. Hotta K, Funahashi T, Arita Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000;20:1595–1599.
82. Weyer C, Funahashi T, Tanaka S, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001;86:1930–1935.
83. Yu JG, Javorschi S, Hevener AL, et al. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes 2002;51:2968–2974.
84. Hotta K, Funahashi T, Bodkin NL, et al. Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diabetes 2001;50:1126–1133.
85. Lindsay RS, Funahashi T, Hanson RL, et al. Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 2002;360:57–58.
86. Lihn AS, Ostergard T, Nyholm B, et al. Adiponectin mRNA expression in subcutaneous adipose tissue is reduced in first-degree relatives of type 2 diabetic patients. Am J Physiol Endocrinol Metab 2003;284(2):443–448.
87. Yang WS, Lee WJ, Funahashi T, et al. Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metab 2001;86:3815–3819.
88. Berg AH, Combs TP, Du X, et al. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 2001;7:947–953.
89. Combs TP, Wagner JA, Berger J, et al. Induction of adipocyte complement-related protein of 30 kilodaltons by PPARgamma agonists: a potential mechanism of insulin sensitization. Endocrinology 2002; 143:998–1007.
90. Fruebis J, Tsao TS, Javorschi S, et al. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci USA 2001;98:2005–2010.
91. Combs TP, Berg AH, Obici S, et al. Endogenous glucose production is inhibited by the adipose-derived protein Acrp30. J Clin Invest 2001;108:1875–1881.
92. Ouchi N, Kihara S, Arita Y, et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 1999;100:2473–2476.
93. Ouchi N, Kihara S, Arita Y, et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation 2000;102:1296–1301.
94. Ouchi N, Kihara S, Arita Y, et al. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 2001;103:1057–1063.
95. Okamoto Y, Arita Y, Nishida M, et al. An adipocyte-derived plasma protein, adiponectin, adheres to injured vascular walls. Horm Metab Res 2000;32:47–50.
96. Yokota T, Oritani K, Takahashi I, et al. Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood 2000;96:1723–1732.
97. Yamauchi T, Kamon J, Minokoshi Y, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002;8(11):1288–1295.
98. Tomas E, Tsao TS, Saha AK, et al. Enhanced muscle fat oxidation and glucose transport by ACRP30 globular domain: acetyl-CoA carboxylase inhibition and AMP-activated protein kinase activation. Proc Natl Acad Sci USA 2002;99:16309–16313.
99. Ruderman NB, Saha AK, Vavvas D, et al. Malonyl-CoA, fuel sensing, and insulin resistance. Am J Physiol 1999;276:E1–E18.
100. Hayashi T, Hirshman MF, Fujii N, et al. Metabolic stress and altered glucose transport: activation of AMP-activated protein kinase as a unifying coupling mechanism. Diabetes 2000;49:527–531.
101. Winder WW, Hardie DG. AMP-activated protein kinase, a metabolic master switch: possible roles in type 2 diabetes. Am J Physiol 1999;277:E1–E10.
102. Park H, Kaushik VK, Constant S, et al. Coordinate regulation of malonyl-CoA decarboxylase, sn-glycerol-3-phosphate acyltransferase, and acetyl-CoA carboxylase by AMP-activated protein kinase in rat tissues in response to exercise. J Biol Chem 2002;277:32571–32577.
103. Wu X, Motoshima H, Mahadev K, et al. Involvement of AMP-activated protein kinase in glucose uptake stimulated by the globular domain of adiponectin in primary rat adipocytes. Diabetes 2003;52: 1355–1363.
104. Yamauchi T, Kamon J, Ito Y, et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003;423:762–769.
105. Kissebah AH, Sonnenberg GE, Myklebust J, et al. Quantitative trait loci on chromosomes 3 and 17 influence phenotypes of the metabolic syndrome. Proc Natl Acad Sci USA 2000;97:14478–14483.
106. Saito K, Tobe T, Minoshima S, et al. Organization of the gene for gelatin-binding protein (GBP28). Gene 1999;229:67–73.
107. Takahashi M, Arita Y, Yamagata K, et al. Genomic structure and mutations in adipose-specific gene, adiponectin. Int J Obes Rel Metab Disord 2000;24:861–868.
108. Vionnet N, Hani El H, Dupont S, et al. Genomewide search for type 2 diabetes-susceptibility genes in French whites: evidence for a novel susceptibility locus for early-onset diabetes on chromosome 3q27-qter and independent replication of a type 2-diabetes locus on chromosome 1q21-q24. Am J Hum Genet 2000;67:1470–1480.
109. Vasseur F, Helbecque N, Dina C, et al. Single-nucleotide polymorphism haplotypes in the both proximal promoter and exon 3 of the APM1 gene modulate adipocyte-secreted adiponectin hormone levels and contribute to the genetic risk for type 2 diabetes in French Caucasians. Hum Mol Genet 2002;11:2607–2614.
110. Menzaghi C, Ercolino T, Di Paola R, et al. A haplotype at the adiponectin locus is associated with obesity and other features of the insulin resistance syndrome. Diabetes 2002;51:2306–2312.
111. Kondo H, Shimomura I, Matsukawa Y, et al. Association of adiponectin mutation with type 2 diabetes: a candidate gene for the insulin resistance syndrome. Diabetes 2002;51:2325–2328.
112. Maeda N, Shimomura I, Kishida K, et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 2002;8:731–737.
113. Kubota N, Terauchi Y, Yamauchi T, et al. Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem 2002;277:25863–25866.
114. Ma K, Cabrero A, Saha PK, et al. Increased beta-oxidation but no insulin resistance or glucose intolerance in mice lacking adiponectin. J Biol Chem 2002;31:31.
115. Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 2001;104:487–501.
116. Seals DF, Courtneidge SA. The ADAMs family of metalloproteases: multidomain proteins with multiple functions. Genes Dev 2003;17: 7–30.
117. Hotamisligil GS, Arner P, Atkinson RL, et al. Differential regulation of the p80 tumor necrosis factor receptor in human obesity and insulin resistance. Diabetes 1997;46:451–455.
118. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993;259:87–91.
119. Lang CH, Dobrescu C, Bagby GJ. Tumor necrosis factor impairs insulin action on peripheral glucose disposal and hepatic glucose output. Endocrinology 1992;130:43–52.
120. Uysal KT, Wiesbrock SM, Marino MW, et al. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature 1997;389:610–614.
121. Liu LS, Spelleken M, Rohrig K, et al. Tumor necrosis factor-alpha acutely inhibits insulin signaling in human adipocytes: implication of the p80 tumor necrosis factor receptor. Diabetes 1998;47:515–522.
122. Feinstein R, Kanety H, Papa MZ, et al. Tumor necrosis factor-alpha suppresses insulin-induced tyrosine phosphorylation of insulin receptor and its substrates. J Biol Chem 1993;268:26055–26058.
123. Ozes ON, Akca H, Mayo LD, et al. A phosphatidylinositol 3-kinase/ Akt/mTOR pathway mediates and PTEN antagonizes tumor necrosis factor inhibition of insulin signaling through insulin receptor substrate-1. Proc Natl Acad Sci USA 2001;98:4640–4645.
124. Guo D, Donner DB. Tumor necrosis factor promotes phosphorylation and binding of insulin receptor substrate 1 to phosphatidylinositol 3-kinase in 3T3-L1 adipocytes. J Biol Chem 1996;271:615–618.
125. Ruan H, Miles PD, Ladd CM, et al. Profiling gene transcription in vivo reveals adipose tissue as an immediate target of tumor necrosis factor-alpha: implications for insulin resistance. Diabetes 2002;51: 3176–3188.
126. Wolvekamp MC, Marquet RL. Interleukin-6: historical background, genetics and biological significance. Immunol Lett 1990;24:1–9.
127. Barkhudaryan N, Dunn AJ. Molecular mechanisms of actions of interleukin-6 on the brain, with special reference to serotonin and the hypothalamo-pituitary-adrenocortical axis. Neurochem Res 1999;24: 1169–1180.
128. Ikebuchi K, Wong GG, Clark SC, et al. Interleukin 6 enhancement of interleukin 3-dependent proliferation of multipotential hemopoietic progenitors. Proc Natl Acad Sci USA 1987;84:9035–9039.
129. Taga T, Kishimoto T. Gp130 and the interleukin-6 family of cytokines. Annu Rev Immunol 1997;15:797–819.
130. Sehgal PB. Interleukin-6: a regulator of plasma protein gene expression in hepatic and non-hepatic tissues. Mol Biol Med 1990;7: 117–130.
131. Kishimoto T, Hibi M, Murakami M, et al. The molecular biology of interleukin 6 and its receptor. CIBA Found Symp 1992;167:5–16; discussion 16–23.
132. Fey GH, Hattori M, Hocke G, et al. Gene regulation by interleukin 6. Biochimie 1991;73:47–50.
133. Mohamed-Ali V, Goodrick S, Rawesh A, et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab 1997;82:4196–4200.
134. Fried SK, Bunkin DA, Greenberg AS. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. J Clin Endocrinol Metab 1998;83:847–850.
135. Somers W, Stahl M, Seehra JS. 1.9 A crystal structure of interleukin 6: implications for a novel mode of receptor dimerization and signaling. Embo J 1997;16:989–997.
136. Vozarova B, Weyer C, Hanson K, et al. Circulating interleukin-6 in relation to adiposity, insulin action, and insulin secretion. Obes Res 2001;9:414–417.
137. Kern PA, Ranganathan S, Li C, et al. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 2001;280:E745–E751.
138. Bastard JP, Jardel C, Bruckert E, et al. Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss. J Clin Endocrinol Metab 2000;85:3338–3342.
139. Stephens JM, Butts MD, Pekala PH. Regulation of transcription factor mRNA accumulation during 3T3-L1 preadipocyte differentiation by tumour necrosis factor-alpha. J Mol Endocrinol 1992;9: 61–72.
140. Coppack SW. Pro-inflammatory cytokines and adipose tissue. Proc Nutr Soc 2001;60:349–356.
141. Mohamed-Ali V, Flower L, Sethi J, et al. Beta-adrenergic regulation of IL-6 release from adipose tissue: in vivo and in vitro studies. J Clin Endocrinol Metab 2001;86:5864–5869.
142. Vicennati V, Vottero A, Friedman C, et al. Hormonal regulation of interleukin-6 production in human adipocytes. Int J Obes Relat Metab Disord 2002;26:905–911.
143. Path G, Bornstein SR, Gurniak M, et al. Human breast adipocytes express interleukin-6 (IL-6) and its receptor system: increased IL-6 production by beta-adrenergic activation and effects of IL-6 on adipocyte function. J Clin Endocrinol Metab 2001;86:2281–2288.
144. Greenberg AS, Nordan RP, McIntosh J, et al. Interleukin 6 reduces lipoprotein lipase activity in adipose tissue of mice in vivo and in 3T3-L1 adipocytes: a possible role for interleukin 6 in cancer cachexia. Cancer Res 1992;52:4113–4116.
145. Hardardottir I, Grunfeld C, Feingold KR. Effects of endotoxin on lipid metabolism. Biochem Soc Trans 1995;23:1013–1018.
146. Lyngso D, Simonsen L, Bulow J. Metabolic effects of interleukin-6 in human splanchnic and adipose tissue. J Physiol 2002;543:379–386.
147. Papanicolaou DA, Wilder RL, Manolagas SC, et al. The pathophysiologic roles of interleukin-6 in human disease. Ann Intern Med 1998; 128:127–137.
148. Plata-Salaman CR. Central nervous system mechanisms contributing to the cachexia-anorexia syndrome. Nutrition 2000;16:1009–1012.
149. Jones TH, Kennedy RL. Cytokines and hypothalamic-pituitary function. Cytokine 1993;5:531–538.
150. Wallenius V, Wallenius K, Ahren B, et al. Interleukin-6-deficient mice develop mature-onset obesity. Nat Med 2002;8:75–79.
151. Steppan CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes. Nature 2001;409:307–312.
152. Kim KH, Lee K, Moon YS, et al. A cysteine-rich adipose tissue-specific secretory factor inhibits adipocyte differentiation. J Biol Chem 2001;276:11252–11256.
153. Holcomb IN, Kabakoff RC, Chan B, et al. FIZZ1, a novel cysteine-rich secreted protein associated with pulmonary inflammation, defines a new gene family. Embo J 2000;19:4046–4055.
154. Banerjee RR, Lazar MA. Resistin: molecular history and prognosis. J Mol Med 2003;81:218–226.
155. Steppan CM, Brown EJ, Wright CM, et al. A family of tissue-specific resistin-like molecules. Proc Natl Acad Sci USA 2001;98:502–506.
156. Banerjee RR, Lazar MA. Dimerization of resistin and resistin-like molecules is determined by a single cysteine. J Biol Chem 2001; 276:25970–25973.
157. Juan CC, Kan LS, Huang CC, et al. Production and characterization of bioactive recombinant resistin in Escherichia coli. J Biotechnol 2003;103:113–117.
158. Moon B, Kwan JJ, Duddy N, et al. Resistin inhibits glucose uptake in L6 cells independently of changes in insulin signaling and GLUT4 translocation. Am J Physiol Endocrinol Metab 2003;285: E106–E115.
159. Rajala MW, Obici S, Scherer PE, et al. Adipose-derived resistin and gut-derived resistin-like molecule-beta selectively impair insulin action on glucose production. J Clin Invest 2003;111:225–230.
160. Li J, Yu X, Pan W, et al. Gene expression profile of rat adipose tissue at the onset of high-fat-diet obesity. Am J Physiol Endocrinol Metab 2002;282:E1334–E1341.
161. Fukui Y, Motojima K. Expression of resistin in the adipose tissue is modulated by various factors including peroxisome proliferator-activated receptor alpha. Diabetes Obes Metab 2002;4:342–345.
162. Way JM, Gorgun CZ, Tong Q, et al. Adipose tissue resistin expression is severely suppressed in obesity and stimulated by peroxisome proliferator-activated receptor gamma agonists. J Biol Chem 2001; 276:25651–25653.
163. Fujita H, Fujishima H, Morii T, et al. Effect of metformin on adipose tissue resistin expression in db/db mice. Biochem Biophys Res Commun 2002;298:345–349.
164. Le Lay S, Boucher J, Rey A, et al. Decreased resistin expression in mice with different sensitivities to a high-fat diet. Biochem Biophys Res Commun 2001;289:564–567.
165. Ukkola O. Resistin—a mediator of obesity-associated insulin resistance or an innocent bystander? Eur J Endocrinol 2002;147:571–574.
166. Hotamisligil GS. The irresistible biology of resistin. J Clin Invest 2003;111:173–174.
167. Savage DB, Sewter CP, Klenk ES, et al. Resistin/Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor-gamma action in humans. Diabetes 2001;50:2199–2202.
168. Nagaev I, Smith U. Insulin resistance and type 2 diabetes are not related to resistin expression in human fat cells or skeletal muscle. Biochem Biophys Res Commun 2001;285:561–564.
169. Engeli S, Negrel R, Sharma AM. Physiology and pathophysiology of the adipose tissue renin-angiotensin system. Hypertension 2000;35: 1270–1277.
170. Harp JB, DiGirolamo M. Components of the renin-angiotensin system in adipose tissue: changes with maturation and adipose mass enlargement. J Gerontol 1995;50:B270–B276.
171. Engeli S, Gorzelniak K, Kreutz R, et al. Co-expression of renin-angiotensin system genes in human adipose tissue. J Hypertens 1999; 17:555–560.
172. Karlsson C, Lindell K, Ottosson M, et al. Human adipose tissue expresses angiotensinogen and enzymes required for its conversion to angiotensin II. J Clin Endocrinol Metab 1998;83:3925–3929.
173. Jones BH, Standridge MK, Taylor JW, et al. Angiotensinogen gene expression in adipose tissue: analysis of obese models and hormonal and nutritional control. Am J Physiol 1997;273:R236–R242.
174. Aubert J, Safonova I, Negrel R, et al. Insulin down-regulates angiotensinogen gene expression and angiotensinogen secretion in cultured adipose cells. Biochem Biophys Res Commun 1998;250:77–82.
175. Schling P, Mallow H, Trindl A, et al. Evidence for a local renin angiotensin system in primary cultured human preadipocytes. Int J Obes Rel Metab Disord 1999;23:336–341.
176. Frederich RC Jr, Kahn BB, Peach MJ, et al. Tissue-specific nutritional regulation of angiotensinogen in adipose tissue. Hypertension 1992;19:339–344.
177. Engeli S, Sharma AM. The renin-angiotensin system and natriuretic peptides in obesity-associated hypertension. J Mol Med 2001;79:21–29.
178. Ailhaud G, Fukamizu A, Massiera F, et al. Angiotensinogen, angiotensin II and adipose tissue development. Int J Obes Rel Metab Disord 2000;24(suppl 4):33–35.
179. Janke J, Engeli S, Gorzelniak K, et al. Mature adipocytes inhibit in vitro differentiation of human preadipocytes via angiotensin type 1 receptors. Diabetes 2002;51:1699–1707.
180. Fruhbeck G, Gomez-Ambrosi J, Muruzabal FJ, et al. The adipocyte: a model for integration of endocrine and metabolic signaling in energy metabolism regulation. Am J Physiol Endocrinol Metab 2001; 280:E827–E847.
181. Choy LN, Rosen BS, Spiegelman BM. Adipsin and an endogenous pathway of complement from adipose cells. J Biol Chem 1992; 267:12736–12741.
182. Sniderman AD, Cianflone K. The adipsin-acylation-stimulating protein pathway and microenvironmental metabolic regulation. World Rev Nutr Diet 1997;80:44–81.
183. White RT, Damm D, Hancock N, et al. Human adipsin is identical to complement factor D and is expressed at high levels in adipose tissue. J Biol Chem 1992;267:9210–9213.
184. Esterbauer H, Krempler F, Oberkofler H, et al. The complement system: a pathway linking host defence and adipocyte biology. Eur J Clin Invest 1999;29:653–656.
185. Cook KS, Min HY, Johnson D, et al. Adipsin: a circulating serine protease homolog secreted by adipose tissue and sciatic nerve. Science 1987;237:402–405.
186. Flier JS, Cook KS, Usher P, et al. Severely impaired adipsin expression in genetic and acquired obesity. Science 1987;237:405–408.
187. Pomeroy C, Mitchell J, Eckert E, et al. Effect of body weight and caloric restriction on serum complement proteins, including factor D/adipsin: studies in anorexia nervosa and obesity. Clin Exp Immunol 1997;108:507–515.
188. Napolitano A, Lowell BB, Damm D, et al. Concentrations of adipsin in blood and rates of adipsin secretion by adipose tissue in humans with normal, elevated and diminished adipose tissue mass. Int J Obes Rel Metab Disord 1994;18:213–218.
189. Cianflone K, Maslowska M, Sniderman A. The acylation stimulating protein-adipsin system. Int J Obes Rel Metab Disord 1995;19(suppl 1):34–38.
190. Cianflone K, Maslowska M, Sniderman AD. Acylation stimulating protein (ASP), an adipocyte autocrine: new directions. Semin Cell Dev Biol 1999;10:31–41.
191. Cianflone KM, Sniderman AD, Walsh MJ, et al. Purification and characterization of acylation stimulating protein. J Biol Chem 1989; 264:426–430.
192. Murray I, Sniderman AD, Cianflone K. Enhanced triglyceride clearance with intraperitoneal human acylation stimulating protein in C57BL/6 mice. Am J Physiol 1999;277:E474–E480.
193. Saleh J, Blevins JE, Havel PJ, et al. Acylation stimulating protein (ASP) acute effects on postprandial lipemia and food intake in rodents. Int J Obes Rel Metab Disord 2001;25:705–713.
194. Scantlebury T, Maslowska M, Cianflone K. Chylomicron-specific enhancement of acylation stimulating protein and precursor protein C3 production in differentiated human adipocytes. J Biol Chem 1998;273:20903–20909.
195. Yasruel Z, Cianflone K, Sniderman AD, et al. Effect of acylation stimulating protein on the triacylglycerol synthetic pathway of human adipose tissue. Lipids 1991;26:495–499.
196. Germinario R, Sniderman AD, Manuel S, et al. Coordinate regulation of triacylglycerol synthesis and glucose transport by acylation-stimulating protein. Metabolism 1993;42:574–580.
197. Maslowska M, Sniderman AD, Germinario R, et al. ASP stimulates glucose transport in cultured human adipocytes. Int J Obes Rel Metab Disord 1997;21:261–266.
198. Baldo A, Sniderman AD, St Luce S, et al. Signal transduction pathway of acylation stimulating protein: involvement of protein kinase C. J Lipid Res 1995;36:1415–1426.
199. Murray I, Havel PJ, Sniderman AD, et al. Reduced body weight, adipose tissue, and leptin levels despite increased energy intake in female mice lacking acylation-stimulating protein. Endocrinology 2000;141:1041–1049.
200. Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor beta in human disease. N Engl J Med 2000;342:1350–1358.
201. Clark DA, Coker R. Transforming growth factor-beta (TGF-beta). Int J Biochem Cell Biol 1998;30:293–298.
202. Zhu HJ, Burgess AW. Regulation of transforming growth factor-beta signaling. Mol Cell Biol Res Commun 2001;4:321–330.
203. Alessi MC, Bastelica D, Morange P, et al. Plasminogen activator inhibitor 1, transforming growth factor-beta1, and BMI are closely associated in human adipose tissue during morbid obesity. Diabetes 2000;49:1374–1380.
204. Samad F, Yamamoto K, Pandey M, et al. Elevated expression of transforming growth factor-beta in adipose tissue from obese mice. Mol Med 1997;3:37–48.
205. Sawdey MS, Loskutoff DJ. Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo: tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-alpha, and transforming growth factor-beta. J Clin Invest 1991;88:1346–1353.
206. Gottschling-Zeller H, Birgel M, Rohrig K, et al. Effect of tumor necrosis factor alpha and transforming growth factor beta 1 on plasminogen activator inhibitor-1 secretion from subcutaneous and omental human fat cells in suspension culture. Metabolism 2000;49: 666–671.
207. Sparks RL, Allen BJ, Strauss EE. TGF-beta blocks early but not late differentiation-specific gene expression and morphologic differentiation of 3T3 T proadipocytes. J Cell Physiol 1992;150:568–577.
208. Petruschke T, Rohrig K, Hauner H. Transforming growth factor beta (TGF-beta) inhibits the differentiation of human adipocyte precursor cells in primary culture. Int J Obes Rel Metab Disord 1994;18: 532–536.
209. Xing H, Northrop JP, Grove JR, et al. TNF alpha-mediated inhibition and reversal of adipocyte differentiation is accompanied by suppressed expression of PPARgamma without effects on Pref-1 expression. Endocrinology 1997;138:2776–2783.
210. Torti FM, Torti SV, Larrick JW, et al. Modulation of adipocyte differentiation by tumor necrosis factor and transforming growth factor beta. J Cell Biol 1989;108:1105–1113.
211. Binder BR, Christ G, Gruber F, et al. Plasminogen activator inhibitor 1: physiological and pathophysiological roles. News Physiol Sci 2002;17:56–61.
212. Lundgren CH, Brown SL, Nordt TK, et al. Elaboration of type-1 plasminogen activator inhibitor from adipocytes: a potential pathogenetic link between obesity and cardiovascular disease. Circulation 1996;93:106–110.
213. Samad F, Yamamoto K, Loskutoff DJ. Distribution and regulation of plasminogen activator inhibitor-1 in murine adipose tissue in vivo: induction by tumor necrosis factor-alpha and lipopolysaccharide. J Clin Invest 1996;97:37–46.
214. Alessi MC, Morange P, Juhan-Vague I. Fat cell function and fibrinolysis. Horm Metab Res 2000;32:504–508.
215. Mutch NJ, Wilson HM, Booth NA. Plasminogen activator inhibitor-1 and haemostasis in obesity. Proc Nutr Soc 2001;60:341–347.
216. Menashi S, Lu H, Soria C, et al. Endothelial cell proteases: physiological role and regulation. Baillieres Clin Haematol 1993;6:559–576.
217. Eddy AA. Plasminogen activator inhibitor-1 and the kidney. Am J Physiol Renal Physiol 2002;283:F209–F220.
218. Mertens I, Van Gaal LF. Obesity, haemostasis and the fibrinolytic system. Obes Rev 2002;3:85–101.
219. Samad F, Loskutoff DJ. Tissue distribution and regulation of plasminogen activator inhibitor-1 in obese mice. Mol Med 1996;2:568–582.
220. Cigolini M, Targher G, Bergamo Andreis IA, et al. Visceral fat accumulation and its relation to plasma hemostatic factors in healthy men. Arterioscler Thromb Vasc Biol 1996;16:368–374.
221. Mertens I, Van der Planken M, Corthouts B, et al. Visceral fat is a determinant of PAI-1 activity in diabetic and non-diabetic overweight and obese women. Horm Metab Res 2001;33:602–607.
222. Shimomura I, Funahashi T, Takahashi M, et al. Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity. Nat Med 1996;2:800–803.
223. Camerer E, Kolsto AB, Prydz H. Cell biology of tissue factor, the principal initiator of blood coagulation. Thromb Res 1996;81:1–41.
224. Harlos K, Martin DM, O’Brien DP, et al. Crystal structure of the extracellular region of human tissue factor. Nature 1994;370:662–666.
225. Rauch U, Nemerson Y. Tissue factor, the blood, and the arterial wall. Trends Cardiovasc Med 2000;10:139–143.
226. Drake TA, Morrissey JH, Edgington TS. Selective cellular expression of tissue factor in human tissues: implications for disorders of hemostasis and thrombosis. Am J Pathol 1989;134:1087–1097.
227. Riewald M, Ruf W. Orchestration of coagulation protease signaling by tissue factor. Trends Cardiovasc Med 2002;12:149–154.
228. Macfarlane SR, Seatter MJ, Kanke T, et al. Proteinase-activated receptors. Pharmacol Rev 2001;53:245–282.
229. Samad F, Pandey M, Loskutoff DJ. Tissue factor gene expression in the adipose tissues of obese mice. Proc Natl Acad Sci USA 1998;95: 7591–7596.
230. Chen J, Bierhaus A, Schiekofer S, et al. Tissue factor—a receptor involved in the control of cellular properties, including angiogenesis. Thromb Haemost 2001;86:334–345.
231. Abe K, Shoji M, Chen J, et al. Regulation of vascular endothelial growth factor production and angiogenesis by the cytoplasmic tail of tissue factor. Proc Natl Acad Sci USA 1999;96:8663–8668.
232. Carmeliet P, Moons L, Dewerchin M, et al. Insights in vessel development and vascular disorders using targeted inactivation and transfer of vascular endothelial growth factor, the tissue factor receptor, and the plasminogen system. Ann NY Acad Sci 1997;811:191–206.
233. Samad F, Pandey M, Loskutoff DJ. Regulation of tissue factor gene expression in obesity. Blood 2001;98:3353–3358.